PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"32032075","Response to Black et al","Brenner DM, Sayuk GS, Gutman CR, Jo E, Elmes SJR, Liu LWC, Cash BD.","Am J Gastroenterol. 2020 Mar;115(3):484-485. doi: 10.14309/ajg.0000000000000550.","Brenner DM","Am J Gastroenterol","2020","2020/02/08","","","10.14309/ajg.0000000000000550"
"31972619","Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea","Black CJ, Houghton LA, Ford AC.","Am J Gastroenterol. 2020 Mar;115(3):483-484. doi: 10.14309/ajg.0000000000000518.","Black CJ","Am J Gastroenterol","2020","2020/01/24","","","10.14309/ajg.0000000000000518"
"31466958","Eluxadoline-induced pancreatitis occurring in an adult man without a prior cholecystectomy","Shahid Z, Packard E, Groff A, Jain R.","BMJ Case Rep. 2019 Aug 28;12(8):e231185. doi: 10.1136/bcr-2019-231185.","Shahid Z","BMJ Case Rep","2019","2019/08/31","PMC6720687","","10.1136/bcr-2019-231185"
"31356229","Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study","Brenner DM, Sayuk GS, Gutman CR, Jo E, Elmes SJR, Liu LWC, Cash BD.","Am J Gastroenterol. 2019 Sep;114(9):1502-1511. doi: 10.14309/ajg.0000000000000327.","Brenner DM","Am J Gastroenterol","2019","2019/07/30","PMC6738625","","10.14309/ajg.0000000000000327"
"31205133","Response to Lai","Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.","Am J Gastroenterol. 2019 Jul;114(7):1177-1178. doi: 10.14309/ajg.0000000000000312.","Cash BD","Am J Gastroenterol","2019","2019/06/18","","","10.14309/ajg.0000000000000312"
"30920418","Safety of Eluxadoline Use","Lai SW.","Am J Gastroenterol. 2019 Jul;114(7):1176-1177. doi: 10.14309/ajg.0000000000000205.","Lai SW","Am J Gastroenterol","2019","2019/03/29","","","10.14309/ajg.0000000000000205"
"30588698","Letter: eluxadoline-associated acute pancreatitis-myth or reality?","Garcia-Gonzalez F, Faghih M, Singh V.","Aliment Pharmacol Ther. 2018 Aug;48(4):490-491. doi: 10.1111/apt.14846.","Garcia-Gonzalez F","Aliment Pharmacol Ther","2018","2018/12/28","","","10.1111/apt.14846"
"30588693","Letter: eluxadoline-associated acute pancreatitis-myth or reality? Authors' reply","Harinstein L, Wu E, Brinker A.","Aliment Pharmacol Ther. 2018 Aug;48(4):491-492. doi: 10.1111/apt.14851.","Harinstein L","Aliment Pharmacol Ther","2018","2018/12/28","","","10.1111/apt.14851"
"30502553","High sensitive LC-MS/MS method for estimation of eluxadoline in human plasma and its application to pharmacokinetic study","Dodda S, Makula A, Polagani SR, Kandhagatla RN.","J Pharm Biomed Anal. 2019 Feb 20;165:65-72. doi: 10.1016/j.jpba.2018.11.056. Epub 2018 Nov 24.","Dodda S","J Pharm Biomed Anal","2019","2018/12/04","","","10.1016/j.jpba.2018.11.056"
"30293448","Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome","Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL.","Curr Med Res Opin. 2019 Mar;35(3):461-472. doi: 10.1080/03007995.2018.1533456. Epub 2018 Nov 22.","Olden KW","Curr Med Res Opin","2019","2018/10/09","","","10.1080/03007995.2018.1533456"
"30267294","The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea","Abel JL, Carson RT, Andrae DA.","Qual Life Res. 2019 Feb;28(2):369-377. doi: 10.1007/s11136-018-2008-z. Epub 2018 Sep 28.","Abel JL","Qual Life Res","2019","2018/09/30","PMC6373309","","10.1007/s11136-018-2008-z"
"30189347","Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?","Pannemans J, Corsetti M.","Curr Opin Pharmacol. 2018 Dec;43:53-58. doi: 10.1016/j.coph.2018.08.008. Epub 2018 Sep 3.","Pannemans J","Curr Opin Pharmacol","2018","2018/09/07","","","10.1016/j.coph.2018.08.008"
"30001114","Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators","Zheng Y, Obeng S, Wang H, Stevens DL, Komla E, Selley DE, Dewey WL, Akbarali HI, Zhang Y.","ACS Chem Neurosci. 2018 Dec 19;9(12):3028-3037. doi: 10.1021/acschemneuro.8b00234. Epub 2018 Jul 23.","Zheng Y","ACS Chem Neurosci","2018","2018/07/13","PMC6344324","NIHMS989182","10.1021/acschemneuro.8b00234"
"29894043","Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report","Chhaparia A, Hammami MB, Vareedayah A, Schroeder K.","Del Med J. 2017 Mar;89(3):90-92.","Chhaparia A","Del Med J","2017","2018/06/13","","",""
"29858888","[Drug innovation and reverse thinking]","Guo ZR.","Yao Xue Xue Bao. 2016 Mar;51(3):325-31.","Guo ZR","Yao Xue Xue Bao","2016","2018/06/03","","",""
"29659201","Evaluation of Eluxadoline Effect on Cardiac Repolarization","Bonifacio L, Hunt TL, McIntyre G, Dove LS, Covington PS.","Clin Pharmacol Drug Dev. 2018 Sep;7(7):727-736. doi: 10.1002/cpdd.453. Epub 2018 Apr 16.","Bonifacio L","Clin Pharmacol Drug Dev","2018","2018/04/17","PMC6175186","","10.1002/cpdd.453"
"29644734","Editorial: the sphincter of Oddi strikes again-eluxadoline illuminates a controversial mechanism for the pathogenesis of acute pancreatitis","Coté GA.","Aliment Pharmacol Ther. 2018 May;47(9):1324-1325. doi: 10.1111/apt.14596.","Coté GA","Aliment Pharmacol Ther","2018","2018/04/13","","","10.1111/apt.14596"
"29451407","Advancements in drug development for diarrhea-predominant irritable bowel syndrome","Dothel G, Barbaro MR, Raschi E, Barbara G, De Ponti F.","Expert Opin Investig Drugs. 2018 Mar;27(3):251-263. doi: 10.1080/13543784.2018.1442434. Epub 2018 Feb 22.","Dothel G","Expert Opin Investig Drugs","2018","2018/02/17","","","10.1080/13543784.2018.1442434"
"29349789","Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder","Harinstein L, Wu E, Brinker A.","Aliment Pharmacol Ther. 2018 Mar;47(6):809-815. doi: 10.1111/apt.14504. Epub 2018 Jan 19.","Harinstein L","Aliment Pharmacol Ther","2018","2018/01/20","","","10.1111/apt.14504"
"29155353","Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline","Chedid V, Vijayvargiya P, Camilleri M.","Clin Gastroenterol Hepatol. 2018 Mar;16(3):336-338. doi: 10.1016/j.cgh.2017.11.025. Epub 2017 Nov 16.","Chedid V","Clin Gastroenterol Hepatol","2018","2017/11/21","PMC5816691","NIHMS921681","10.1016/j.cgh.2017.11.025"
"29121571","High throughput μ-SPE based elution coupled with UPLC-MS/MS for determination of eluxadoline in plasma sample: Application in pharmacokinetic characterization of PLGA nanoparticle formulations in rats","Iqbal M, Ezzeldin E, Al-Rashood KA, Al-Shdefat R, Anwer MK.","J Pharm Biomed Anal. 2018 Feb 5;149:172-178. doi: 10.1016/j.jpba.2017.10.024. Epub 2017 Oct 28.","Iqbal M","J Pharm Biomed Anal","2018","2017/11/10","","","10.1016/j.jpba.2017.10.024"
"29033544","Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome","Özdener AE, Rivkin A.","Drug Des Devel Ther. 2017 Sep 26;11:2827-2840. doi: 10.2147/DDDT.S127405. eCollection 2017.","Özdener AE","Drug Des Devel Ther","2017","2017/10/17","PMC5628681","","10.2147/DDDT.S127405"
"28978966","Safety of Eluxadoline in Patients With Irritable Bowel Syndrome","Croteau R, Barkin JS.","Am J Gastroenterol. 2017 Oct;112(10):1616. doi: 10.1038/ajg.2017.249.","Croteau R","Am J Gastroenterol","2017","2017/10/06","","","10.1038/ajg.2017.249"
"28978962","Response to Croteau and Barkin","Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.","Am J Gastroenterol. 2017 Oct;112(10):1617. doi: 10.1038/ajg.2017.256.","Cash BD","Am J Gastroenterol","2017","2017/10/06","","","10.1038/ajg.2017.256"
"28978951","Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder","Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.","Am J Gastroenterol. 2017 Oct;112(10):1619-1620. doi: 10.1038/ajg.2017.257.","Cash BD","Am J Gastroenterol","2017","2017/10/06","","","10.1038/ajg.2017.257"
"28808082","Τ Eluxadoline for IBS-D","","Drug Ther Bull. 2017 Aug;55(8):91-92. doi: 10.1136/dtb.2017.8.0515.","","Drug Ther Bull","2017","2017/08/16","","","10.1136/dtb.2017.8.0515"
"28808081","▼ Eluxadoline for IBS-D","","Drug Ther Bull. 2017 Aug;55(8):90-93. doi: 10.1136/dtb.2017.8.0514.","","Drug Ther Bull","2017","2017/08/16","","","10.1136/dtb.2017.8.0514"
"28804032","Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline","Gawron AJ, Bielefeldt K.","Clin Gastroenterol Hepatol. 2018 Mar;16(3):378-384.e2. doi: 10.1016/j.cgh.2017.08.006. Epub 2017 Aug 10.","Gawron AJ","Clin Gastroenterol Hepatol","2018","2017/08/15","","","10.1016/j.cgh.2017.08.006"
"28747053","Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective","Vera I, Júdez FJ.","Rev Esp Enferm Dig. 2017 Nov;109(11):788-794. doi: 10.17235/reed.2017.5078/2017.","Vera I","Rev Esp Enferm Dig","2017","2017/07/28","","","10.17235/reed.2017.5078/2017"
"28719721","Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics","Marbury TC, Berg JK, Dove LS, Covington PS.","J Clin Pharmacol. 2017 Nov;57(11):1454-1459. doi: 10.1002/jcph.964. Epub 2017 Jul 18.","Marbury TC","J Clin Pharmacol","2017","2017/07/19","PMC5655746","","10.1002/jcph.964"
"28493170","Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome","Keating GM.","Drugs. 2017 Jun;77(9):1009-1016. doi: 10.1007/s40265-017-0756-7.","Keating GM","Drugs","2017","2017/05/12","","","10.1007/s40265-017-0756-7"
"28419076","In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder","","Med Lett Drugs Ther. 2017 Apr 24;59(1519):70.","","Med Lett Drugs Ther","2017","2017/04/19","","",""
"28417992","Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use","Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS.","Am J Gastroenterol. 2017 Jun;112(6):924-932. doi: 10.1038/ajg.2017.72. Epub 2017 Apr 18.","Lacy BE","Am J Gastroenterol","2017","2017/04/19","PMC5465428","","10.1038/ajg.2017.72"
"28326568","Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies","Chey WD, Dove LS, Andrae DA, Covington PS.","Aliment Pharmacol Ther. 2017 May;45(10):1319-1328. doi: 10.1111/apt.14031. Epub 2017 Mar 22.","Chey WD","Aliment Pharmacol Ther","2017","2017/03/23","PMC5413805","","10.1111/apt.14031"
"28276811","New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline","Corsetti M, Whorwell P.","Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):285-292. doi: 10.1080/17474124.2017.1298442. Epub 2017 Mar 1.","Corsetti M","Expert Rev Gastroenterol Hepatol","2017","2017/03/10","","","10.1080/17474124.2017.1298442"
"28232472","Dietary and pharmacological treatment of abdominal pain in IBS","Camilleri M, Boeckxstaens G.","Gut. 2017 May;66(5):966-974. doi: 10.1136/gutjnl-2016-313425. Epub 2017 Feb 23.","Camilleri M","Gut","2017","2017/02/25","","","10.1136/gutjnl-2016-313425"
"28167156","Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea","Fant RV, Henningfield JE, Cash BD, Dove LS, Covington PS.","Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.","Fant RV","Clin Gastroenterol Hepatol","2017","2017/02/08","","","10.1016/j.cgh.2017.01.026"
"27922029","Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea","Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.","Am J Gastroenterol. 2017 Feb;112(2):365-374. doi: 10.1038/ajg.2016.542. Epub 2016 Dec 6.","Cash BD","Am J Gastroenterol","2017","2016/12/07","PMC5318664","","10.1038/ajg.2016.542"
"27875419","New treatment options for irritable bowel syndrome with predominant diarrhea","Weber HC.","Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):25-30. doi: 10.1097/MED.0000000000000302.","Weber HC","Curr Opin Endocrinol Diabetes Obes","2017","2016/11/23","","","10.1097/MED.0000000000000302"
"27647873","Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist","Levy-Cooperman N, McIntyre G, Bonifacio L, McDonnell M, Davenport JM, Covington PS, Dove LS, Sellers EM.","J Pharmacol Exp Ther. 2016 Dec;359(3):471-481. doi: 10.1124/jpet.116.236547. Epub 2016 Sep 19.","Levy-Cooperman N","J Pharmacol Exp Ther","2016","2016/09/21","PMC5118645","","10.1124/jpet.116.236547"
"27527743","Board Review Vignette: Irritable Bowel Syndrome","Talley NJ.","Am J Gastroenterol. 2016 Sep;111(9):1223-5. doi: 10.1038/ajg.2016.317. Epub 2016 Aug 16.","Talley NJ","Am J Gastroenterol","2016","2016/08/17","","","10.1038/ajg.2016.317"
"27436200","Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations","Lacy BE, Moreau JC.","J Am Assoc Nurse Pract. 2016 Jul;28(7):393-404. doi: 10.1002/2327-6924.12387.","Lacy BE","J Am Assoc Nurse Pract","2016","2016/07/21","","","10.1002/2327-6924.12387"
"27331917","Modern Management of Irritable Bowel Syndrome: More Than Motility","Tack J, Vanuytsel T, Corsetti M.","Dig Dis. 2016;34(5):566-73. doi: 10.1159/000445265. Epub 2016 Jun 22.","Tack J","Dig Dis","2016","2016/06/23","","","10.1159/000445265"
"27267380","Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome","Scarpellini E, Laterza L, Ianiro G, Tack J, Abenavoli L, Gasbarrini A.","Expert Opin Pharmacother. 2016 Jul;17(10):1395-402. doi: 10.1080/14656566.2016.1182982. Epub 2016 Jun 8.","Scarpellini E","Expert Opin Pharmacother","2016","2016/06/09","","","10.1080/14656566.2016.1182982"
"27191492","Drug development: A healthy pipeline","Morgan B.","Nature. 2016 May 19;533(7603):S116-7. doi: 10.1038/533S116a.","Morgan B","Nature","2016","2016/05/19","","","10.1038/533S116a"
"27156944","Eluxadoline, Lesinurad, and Idarucizumab","Hussar DA, Gandhi M.","J Am Pharm Assoc (2003). 2016 May-Jun;56(3):343-6. doi: 10.1016/j.japh.2016.04.559.","Hussar DA","J Am Pharm Assoc (2003)","2016","2016/05/10","","","10.1016/j.japh.2016.04.559"
"27078238","[Therapy for irritable bowel syndrome in sight?]","Frieling T.","Dtsch Med Wochenschr. 2016 Apr;141(8):526. doi: 10.1055/s-0042-101296. Epub 2016 Apr 14.","Frieling T","Dtsch Med Wochenschr","2016","2016/04/15","","","10.1055/s-0042-101296"
"27062744","The latest drug therapies for treating IBS. Longtime sufferers of irritable bowel syndrome have new options for relief","","Health After 50 Sci Am Consum Health. 2015 Dec;27(12):3.","","Health After 50 Sci Am Consum Health","2015","2016/04/12","","",""
"26979218","[A new remedy for diarrheal irritable bowel syndrome]","Storr M.","MMW Fortschr Med. 2016 Mar 17;158(5):43. doi: 10.1007/s15006-016-7937-2.","Storr M","MMW Fortschr Med","2016","2016/03/17","","","10.1007/s15006-016-7937-2"
"26971716","Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline","Rivkin A, Rybalov S.","Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11.","Rivkin A","Pharmacotherapy","2016","2016/03/15","","","10.1002/phar.1712"
"26789872","Eluxadoline for Irritable Bowel Syndrome with Diarrhea","Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, Covington PS.","N Engl J Med. 2016 Jan 21;374(3):242-53. doi: 10.1056/NEJMoa1505180.","Lembo AJ","N Engl J Med","2016","2016/01/21","","","10.1056/NEJMoa1505180"
"26714241","Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea","","Med Lett Drugs Ther. 2016 Jan 4;58(1485):4-5.","","Med Lett Drugs Ther","2016","2015/12/30","","",""
"26690872","Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS","Lacy BE.","Neurogastroenterol Motil. 2016 Jan;28(1):26-35. doi: 10.1111/nmo.12716.","Lacy BE","Neurogastroenterol Motil","2016","2015/12/23","","","10.1111/nmo.12716"
"26559529","Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?","Cash BD, Lacy BE, Rao T, Earnest DL.","Expert Opin Pharmacother. 2016;17(3):311-22. doi: 10.1517/14656566.2016.1118052. Epub 2015 Dec 8.","Cash BD","Expert Opin Pharmacother","2016","2015/11/13","","","10.1517/14656566.2016.1118052"
"26558923","Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome","Nee J, Zakari M, Lembo AJ.","Expert Opin Pharmacother. 2015;16(18):2781-92. doi: 10.1517/14656566.2015.1101449. Epub 2015 Nov 11.","Nee J","Expert Opin Pharmacother","2015","2015/11/13","","","10.1517/14656566.2015.1101449"
"26149369","Eluxadoline: First Global Approval","Garnock-Jones KP.","Drugs. 2015 Jul;75(11):1305-10. doi: 10.1007/s40265-015-0436-4.","Garnock-Jones KP","Drugs","2015","2015/07/08","","","10.1007/s40265-015-0436-4"
"26092951","Eluxadoline approved for irritable bowel syndrome with diarrhea","Traynor K.","Am J Health Syst Pharm. 2015 Jul 1;72(13):1078. doi: 10.2146/news150043.","Traynor K","Am J Health Syst Pharm","2015","2015/06/21","","","10.2146/news150043"
"25491493","Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline","Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J.","J Clin Pharmacol. 2015 May;55(5):534-42. doi: 10.1002/jcph.442. Epub 2015 Jan 14.","Davenport JM","J Clin Pharmacol","2015","2014/12/11","PMC4402028","","10.1002/jcph.442"
"25261794","Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers","Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, Devi LA.","Biochem Pharmacol. 2014 Dec 1;92(3):448-56. doi: 10.1016/j.bcp.2014.09.015. Epub 2014 Sep 28.","Fujita W","Biochem Pharmacol","2014","2014/09/28","PMC4769596","NIHMS756900","10.1016/j.bcp.2014.09.015"
"24813429","Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome","Andrae DA, Covington PS, Patrick DL.","Clin Ther. 2014 May;36(5):663-79. doi: 10.1016/j.clinthera.2014.04.009. Epub 2014 May 9.","Andrae DA","Clin Ther","2014","2014/05/13","","","10.1016/j.clinthera.2014.04.009"
"23583433","Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.","Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.","Dove LS","Gastroenterology","2013","2013/04/16","","","10.1053/j.gastro.2013.04.006"
